Teacher Retirement System of Texas Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

Teacher Retirement System of Texas lowered its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 582,478 shares of the life sciences company's stock after selling 66,550 shares during the period. Teacher Retirement System of Texas owned approximately 0.37% of Illumina worth $77,837,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ILMN. Empowered Funds LLC increased its position in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock valued at $516,000 after purchasing an additional 66 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Illumina by 2.4% during the third quarter. Thrivent Financial for Lutherans now owns 61,749 shares of the life sciences company's stock worth $8,052,000 after buying an additional 1,451 shares during the period. Swiss National Bank increased its position in Illumina by 0.5% during the third quarter. Swiss National Bank now owns 472,900 shares of the life sciences company's stock valued at $61,671,000 after acquiring an additional 2,400 shares during the last quarter. Caprock Group LLC raised its stake in shares of Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock valued at $376,000 after acquiring an additional 83 shares during the period. Finally, Prospera Financial Services Inc raised its stake in shares of Illumina by 2.8% in the third quarter. Prospera Financial Services Inc now owns 28,808 shares of the life sciences company's stock valued at $3,757,000 after acquiring an additional 783 shares during the period. 89.42% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

ILMN has been the topic of several analyst reports. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and cut their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a research note on Friday, February 28th. Royal Bank of Canada decreased their price target on Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research note on Wednesday, March 12th. Canaccord Genuity Group cut their price objective on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Finally, Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $140.90.

Illumina Stock Up 0.4 %

Shares of NASDAQ:ILMN traded up $0.36 during trading on Monday, reaching $88.02. The stock had a trading volume of 1,757,090 shares, compared to its average volume of 2,096,337. The firm's 50-day simple moving average is $108.20 and its 200 day simple moving average is $128.26. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The company has a market capitalization of $13.94 billion, a P/E ratio of -11.46, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.